By selecting the Yes option, leaving Amgen.com.sg option you understand that you are leaving the corporate page of Amgen Singapore and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Singapore is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Singapore. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen has built an organization distinguished by world-class scientists with a talent for applying novel approaches to treat disease. Our R&D strategy aims to align and engage our talent, prioritize investments, and seize scientific opportunities.
To support Amgen's drive to serve patients, the R&D organization aims to discover, develop and deliver life changing medicines to patients everywhere. To accomplish this mission, we need to take full advantage of opportunities arising from rapid scientific progress and new technologies. Biotechnology and the data sciences are advancing at blinding speed, opening up immense new possibilities. At the same time, competition within the industry is intensifying, and there are more and steeper barriers to medical access.To keep pace with these rapidly changing opportunities and challenges, Amgen has adopted a dynamic R&D strategy. It is designed to:
Human data can help us identify biomarkers to better track disease prediction and progression, as well as improve clinical trials by finding patients who will benefit most from the medicines we are making.
At Amgen we believe greater understanding can be found by delving deeper into our DNA.
The huge growth of biological data and computational technologies are allowing scientists to perform a wide range of analysis in a much more rapid and cost-effective way than previously possible, even just 20 years prior.
Data science is also changing the way researchers can understand, diagnose, and track diseases for the next generation of first-in-class therapeutics.
deCODE, our Icelandic subsidiary, is leading the way in collection and analysis of genomics and to find meaningful insights by applying a multi-omics approach.
The use of omics in drug development allows us to deliver transformative therapies.
Multispecific drugs harness natural cellular mechanisms that target disease-causing proteins.
Conventional medicines are produced to target a protein and attach that protein to alter its activity.
Today, many diseases have proteins too big or too complex that are hard to tackle with conventional drugs.
This is evolving toward a new approach in drug design called multi specifics.
Multi Specifics use an induced proximity process to bring together a disease target and an effector.
It acts on that target, or it uses built in zip codes that deliver the drug to its site of action.
Multispecifics are shaping the future of medicine in the biopharmaceutical industry to fight against diseases considered untreatable.
They’re using the body’s natural biological mechanisms to reach targets which were considered out of reach previously.
Generative biology reimagines the protein drug discovery and design process by using AI and machine learning-powered computational models.
The sophistication of drug discovery has evolved.
Generative Biology and the convergence of machine learning, AI technology and biology reimagines the protein drug discovery process.
Amgen is exploring this new wave of innovation to predict protein structures and reduce discovery timelines with the goal of increasing success rates.
Leveraging biology insights, AI and machine learning we are moving from the idea of a protein to a medicine.
Making trials smaller, faster, more efficient and more accessible
Amgen is innovating new ways to get medicines to patients faster.
To achieve that, our R&D strategy in clinical trials is focused on leveraging innovative clinical trials design, real world data and digital technologies to accelerate drug development.
We are continuously working to achieve equitable access to clinical trials by improving the diversity of participants in a study and ensuring they are more characteristic of a broader patient population.
Adaptive clinical trials allow continual learning as data is being collected, helping to find new solutions for those who are afflicted with the disease we seek to treat.
We are now evolving the way we think and run clinical trials applying new approaches in design and execution to improve efficiency and flexibility and to increase speed.
